Allterum Therapeutics

Allterum Therapeutics LLC is developing 4A10, an anti-IL-7Rmonoclonal antibody for treating acute lymphoblastic leukemia (ALL), the most common childhood cancer.

The antibody was developed at the National Cancer Institutes (NCI) and licensed exclusively to Fannin Innovation Studio. Allterum was incubated and launched out of Fannin, which has assigned its executed license to. The company is working with national leaders in the ALL space at Baylor College of Medicine, Texas Childrens Hospital, the Childrens Oncology Group (COG), the NCI, and the Leukemia and Lymphoma Society to develop the technology. Allterum will initially focus on treating children with relapsed/refractory T-cell ALL (T-ALL) who currently lack an effective therapy. Allterum Therapeutics has received Orphan Drug Designation as well as Rare Pediatric Disease Designation from the FDA, providing an accelerated path to approval, and potentially qualifying for a Pediatric Priority Review Voucher.

Allterum Therapeutics is a Fannin Innovation Studio company.

3900 Essex Ln
Houston, TX 77027
United States